Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Luis Castro Pineiro Int'l Appln. No. PCT/GB2004/001435 Int'l Date Filed 1 April 2004 (04/01/2004) Serial No.: (To be assigned) Case No.: T1610YP Filed October 3, 2005 For COMBINATION THERAPY FOR ALZHEIMER'S DISEASE Commissioner for Patents

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

> EDPRESS MAIL CERTIFICATE October ? DATE OF DEPOSIT PRESS MAIL NO. EV66060878949
>
> THEREBY CERTIFY THAT THIS CORRESPONDENCE IS EXPRESS MAIL NO. BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313,

JCO5 Rec'd PCT/PTO 03 OCT 2005

Serial No.: Case No.: To be assigned T1610YP

Page

10/55236

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: October 3, 2005

					Taken and Tradental Contect, 0.3 DELYNCHAELT OF COMMERCE		
	bstitute for form 1449A/PTO NFORMATION	DIS	CLOSURE	Application Applic			
CTATEMENT DV ADDI ICANT			DI ICANT	Filing Date	October 3, 20 0/.5.52367		
STATEMENT BY APPLICANT	First Named Inventor	Jose Luis Castro Pineiro					
	(Group Art Unit			
	(use as many sheets	as no	ecessary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	T1610YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		
		US 5,767,124		Michael J. Kaufman et al	06/16/1998		
				·			
	1						
	1						
	1						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
			WO 03/018579		Merck Frosst Canada & Co.	03/06/2004		
			WO 02/060897		Merck & Co., Inc.	08/08/2002		
			WO 02/069970		Merck & Co., Inc. & Merck Frosst Canada & Co.	09/12/2002		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.